Emily Meseck

ESTP Congress
emily.meseck@novartis.com
,

Dr. Emily Meseck is the Global Head of Portfolio Pathology in the Preclinical Safety Group at the Novartis Biomedical Research (Novartis Pharmaceuticals) located in East Hanover NJ. With twenty years’ experience in toxicologic pathology, she has held a range of positions in industry at both contract research organizations and in pharmaceutical companies. Dr. Meseck has also held several leadership positions in the Society of Toxicologic Pathology, including president, scientific symposium planning committee member, member and now chair of the INHAND GESC as well as roles in Diversity, Inclusion and Belonging efforts in the STP and ACT. As a European STP member, Dr. Meseck has been part of the Symposium Organizing Committees for 2024 and 2025 and is also a member of ACT, SOT and ASGCT. A Diplomate of the American College of Veterinary Pathologists as well as the American Board of Toxicology (ABT), Dr. Meseck received her DVM and anatomic pathology residency training at Cornell University College of Veterinary Medicine and completed a Master of Public Health degree with Dartmouth/Geisel School of Medical in 2024.